Imara
IPOPublic · Boston, United States · Founded 2016 · $94.0M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- imarainc.com
- Total Funding
- $94.0M
- Last Round
- $63.0M Series BMar 2019
- Rounds
- 2
- Type
- Public
About
Imara Inc. was a Boston-based clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for sickle cell disease and beta-thalassemia. Founded in 2016, Imara advanced its lead candidate tovinontrine through clinical trials before discontinuing the program in 2022. The company subsequently completed a reverse merger with Enliven Therapeutics in February 2023.
Summary
Imara is a Biotech company based in Boston, United States, founded in 2016. It has raised $94.0M in total across 2 rounds, most recently a $63.0M Series B round in Mar 2019. Investors include OrbiMed, Arix Bioscience and New Enterprise Associates.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...